These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 34709352)

  • 21. The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases.
    Pach J; Valido K; Belzer A; Leventhal JS
    Am J Clin Dermatol; 2024 Jul; 25(4):595-607. PubMed ID: 38767827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cutaneous adverse events caused by immune checkpoint inhibitors.
    Quach HT; Johnson DB; LeBoeuf NR; Zwerner JP; Dewan AK
    J Am Acad Dermatol; 2021 Oct; 85(4):956-966. PubMed ID: 34332798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy.
    Duraisamy P; Panicker VV; Jose WM
    Dermatol Pract Concept; 2023 Jul; 13(3):. PubMed ID: 37557151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach.
    Kawsar A; Hussain K; Muinonen-Martin AJ; Fearfield L
    Br J Dermatol; 2023 Oct; 189(Suppl 1):i3-i10. PubMed ID: 37903072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice.
    Popa LG; Giurcaneanu C; Portelli MG; Mihai MM; Beiu C; Orzan OA; Ion A; Anghel TH
    Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541099
    [No Abstract]   [Full Text] [Related]  

  • 26. Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy.
    Nguyen N; Wan G; Ugwu-Dike P; Alexander NA; Raval N; Zhang S; Jairath R; Phillipps J; Leung B; Roster K; Seo J; Lu C; Tang K; Choi MS; DeSimone MS; Theodosakis N; Amadife M; Cox N; Le TK; Liu F; Chen W; Bai X; Boland G; Liu D; Hurlbert MS; LeBoeuf N; Reynolds KL; Yu KH; Tsao H; Asgari M; Gusev A; Kwatra SG; Semenov YR
    J Am Acad Dermatol; 2023 Jun; 88(6):1308-1316. PubMed ID: 36828138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic accuracy of general dermatologists and supportive oncodermatologists for biopsied cutaneous immune-related adverse events.
    Thompson LL; Said JT; Li EB; Yoon J; Krasnow NA; Molina GE; Polyakov NJ; Foreman RK; LeBoeuf NR; Chen ST
    Support Care Cancer; 2022 Oct; 30(10):7827-7831. PubMed ID: 35804176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy.
    Tang K; Seo J; Tiu BC; Le TK; Pahalyants V; Raval NS; Ugwu-Dike PO; Zubiri L; Naranbhai V; Carrington M; Gusev A; Reynolds KL; LeBoeuf NR; Asgari MM; Kwatra SG; Semenov YR
    JAMA Dermatol; 2022 Feb; 158(2):189-193. PubMed ID: 35019948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of Metastatic Renal Cell Carcinoma Following First-Line Immune Checkpoint Therapy Failure: A Systematic Review.
    Petrelli F; Vavassori I; Rossitto M; Dottorini L
    Cancers (Basel); 2024 Jul; 16(14):. PubMed ID: 39061236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management.
    Pach J; Leventhal JS
    Crit Rev Immunol; 2022; 42(4):1-20. PubMed ID: 37022356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
    Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
    JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The entanglement of extracellular matrix molecules and immune checkpoint inhibitors in cancer: a systematic review of the literature.
    Fejza A; Carobolante G; Poletto E; Camicia L; Schinello G; Di Siena E; Ricci G; Mongiat M; Andreuzzi E
    Front Immunol; 2023; 14():1270981. PubMed ID: 37854588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Chinese expert consensus on diagnosis and treatment of immune checkpoint inhibitor-related skin adverse reactions (2024 edition)].
    ; ;
    Zhonghua Yi Xue Za Zhi; 2024 May; 104(20):1790-1803. PubMed ID: 38782747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study.
    Leung BW; Wan G; Nguyen N; Rashdan H; Zhang S; Chen W; Cohen S; Boland GM; Sullivan RJ; Fadden RM; Kaufman HL; Kwatra SG; LeBoeuf NR; Semenov YR
    J Am Acad Dermatol; 2023 Jun; 88(6):1265-1270. PubMed ID: 36944564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review.
    Nannini S; Koshenkova L; Baloglu S; Chaussemy D; Noël G; Schott R
    J Neurooncol; 2022 May; 157(3):533-550. PubMed ID: 35416575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Management of Dermatologic Toxicities Related to Immune Checkpoint Inhibitors].
    Si X; He C; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhou J; Duan L; Zhang L
    Zhongguo Fei Ai Za Zhi; 2019 Oct; 22(10):639-644. PubMed ID: 31650946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction.
    Cao T; Zhou X; Wu X; Zou Y
    Front Immunol; 2023; 14():1207544. PubMed ID: 37497220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pustular Lichenoid Eruptions Induced by Immune Checkpoint Inhibitors: Two Case Reports and a Review of the Literature.
    Emonet C; Tétart F; Bauvin O; Cellier L; Courville P; Mignard C; Janela-Lapert R; Lefebvre A; Lachkar S; Lechevalier D; Lagarce L; Carvalho P; Tedbirt B
    J Immunother; 2023 Feb-Mar 01; 46(2):59-63. PubMed ID: 36622668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature.
    Liu LL; Skribek M; Harmenberg U; Gerling M
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36878533
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.